SANA

Business Context and Reporting Period

Sana Biotechnology, Inc. (SANA) is a clinical-stage biotechnology company developing engineered cell therapies for Type 1 Diabetes (T1D), B-cell mediated autoimmune diseases, and oncology. The company utilizes two primary platforms: an ex vivo hypoimmune platform (HIP) to create allogeneic cells that evade immune rejection, and an in vivo fusogen platform for cell-specific gene delivery. This Form 10-K covers the fiscal year ended December 31, 2024.

Key Financial Metrics

Note: The company recorded non-cash gains of $8.2 million related to the revaluation of success payment liabilities and contingent consideration in 2024.

Material Changes vs. Prior Period

• Portfolio Prioritization: In November 2024, Sana announced a strategic shift to prioritize T1D, B-cell mediated autoimmune diseases, and refractory B-cell malignancies. Consequently, the company suspended development of SC291 in oncology and the SC379 glial progenitor cell program.
• Workforce Reduction: Associated with the portfolio prioritization, the company reduced its workforce by approximately 45%, incurring approximately $5.8 million in cash-based severance and related costs.
• Clinical Milestones: In early 2025, the company announced positive 4-week and preliminary 12-week results from the UP421 Investigator-Sponsored Trial (IST) for T1D, demonstrating survival and function of transplanted beta cells without immunosuppression.
• Cost Reduction: Research and development expenses decreased by $51.3 million year-over-year, driven by lower personnel costs, reduced third-party manufacturing, and lower research expenses, partially offset by increased clinical development costs.

Guidance, Outlook, and Risks

• Going Concern: Management has concluded there is substantial doubt regarding the company's ability to continue as a going concern. Current capital resources ($152.5 million) are deemed insufficient to fund planned operations for at least one year from the filing date. Additional financing is required.
• Outlook: The company expects operating losses and expenses to decrease in 2025 compared to 2024 due to the portfolio prioritization. It anticipates sharing data from the GLEAM (SC291) and VIVID (SC262) trials in 2025 and filing an IND for SC451 (T1D) as early as 2026.
• Key Risks:
  • Liquidity: Inability to raise additional capital on acceptable terms could force delays or cessation of R&D programs.
  • Regulatory: Novel technologies face uncertain regulatory pathways; the FDA has issued class-wide boxed warnings for CAR T therapies regarding T-cell malignancies.
  • Contingent Liabilities: Significant obligations exist for success payments to Harvard (up to $175 million) and Cobalt (up to $500 million contingent consideration + $500 million success payment), which fluctuate based on stock price and market capitalization.

Investor Verification Checklist

• Cash Runway: Verify the timeline and terms of any new equity or debt financing required to address the "substantial doubt" going concern warning.
• UP421 Data Verification: Confirm the source data verification status of the 12-week UP421 IST results and the timeline for full publication.
• Contingent Liability Valuation: Review the sensitivity of the $113.5 million contingent liability to changes in SANA's stock price and market cap, as these fluctuations significantly impact reported net loss.
• Portfolio Suspension Impact: Assess the financial and strategic implications of suspending the SC291 oncology program and the SC379 glial progenitor program.
• Manufacturing Strategy: Evaluate the progress of the Bothell, Washington manufacturing facility and reliance on CDMOs for clinical supply.